Clinical trials: Platelet-aggregation Inhibitors
Coronary Artery Disease, Antiplatelet Drugs
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and…
- Trial name
- OPTION2 (NCT06451198)
- Testing
- Indobufen, Aspirin, Ticagrelor
- Where
- China
- Volunteers
- 2,846 people
- Sponsor
- Shanghai Zhongshan Hospital
Cardiac Event, Coronary Artery Disease
Comparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy
The study aims to conduct a randomized controlled trial among adults aged 19 years or older who have experienced acute myocardial infarction at least one year prior, or who have other comorbidities such as peripheral arterial…
- Conditions
- Cardiac Event, Coronary Artery Disease, Peripheral Artery Disease, Bleeding
- Trial name
- OACART (NCT07796217)
- Testing
- Aspirin and low-dose rivaroxaban, Clopidogrel with or without aspirin
- Where
- South Korea
- Volunteers
- 2,758 people
- Sponsor
- Seoul National University Bundang Hospital
Cardiovascular Complications, Hemorrhagic Complications
Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery
Non cardiac surgery in patients with coronary stents is complicated with cardiovascular and hemorrhagic events associated with perioperative management of antiplatelet agents.
- Trial name
- RECO (NCT01045850)
- Where
- 53 sites in France
- Volunteers
- 1,312 people
- Sponsor
- University Hospital, Grenoble
Coronary Disease, Cerebral Infarction
The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)
The purpose of this study is to determine the clinically meaningful definition and prevalence of aspirin resistance based on data linking aspirin-dependent laboratory tests to recurrent vascular events in cardiovascular patients…
- Conditions
- Coronary Disease, Cerebral Infarction, Ischemic Attack, Transient
- Trial name
- NCT00250380
- Where
- 23 sites in Japan
- Volunteers
- 583 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Gastro Intestinal Bleeding, Ischaemic Heart Diseases
Gastrointestinal Bleeding is Blood Loss in the Digestive Tract, Classified as Upper or Lower. Ischemic Heart Disease is Due to Blocked Heart Arteries. Antiplatelet Drugs Help Prevent Heart Attacks But Increase GI Bleeding Risk, Especially When Used Together as Dual Therapy.
Gastrointestinal bleeding is blood loss in the digestive tract, classified as upper or lower. Ischemic heart disease is due to blocked heart arteries.
- Conditions
- Gastro Intestinal Bleeding, Ischaemic Heart Diseases, Antiplatelet Drugs, Antiplatelet Drug-related Gastrointestinal Injury
- Trial name
- NCT07125651
- Volunteers
- 112 people
- Sponsor
- Assiut University
Acute Coronary Syndrome
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
- Trial name
- AReMIS (NCT01952392)
- Where
- France
- Volunteers
- 4,992 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases, Acute Coronary Syndrome
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
It is standard treatment to take anti-platelet medication after cardiac catheterization and stent placement to help prevent the formation of blood clots that may cause heart attack or stroke.
- Trial name
- PAPI-2 (NCT01452152)
- Testing
- clopidogrel, prasugrel
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Maryland, Baltimore
Cardiovascular Diseases, Acute Coronary Syndrome
Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence
This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers.
- Trial name
- NCT05474053
- Testing
- Ticagrelor 90mg (Brilique), Ticagrelor 90mg (Ticaloguard)
- Where
- Egypt
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cairo University
Coronary Artery Disease, Coronary Artery Stenosis
Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention
There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve…
- Trial name
- NHIS (NCT06281041)
- Testing
- Antiplatelet Agents
- Where
- South Korea
- Volunteers
- 4,657 people
- Sponsor
- Samsung Medical Center
Platelet Dysfunction Due to Drugs
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
This study aims to assess the effects of low dose ticagrelor on platelet function testing in patients with stable coronary artery disease.
- Trial name
- TWIST (NCT04206176)
- Testing
- Ticagrelor
- Where
- Trinidad and Tobago
- Volunteers
- 25 people
- Sponsor
- The University of The West Indies
Craniocerebral Trauma, Platelet Aggregation Inhibitors
Correct Timing of Head Imaging in Trauma
The aims of this retrospective and monocentric observational study are: to describe patient characteristics and clinical management of patients with traumatic brain injury taking antiplatelet and/or anticoagulation drugs; to…
- Trial name
- CT-HIT (NCT05306951)
- Testing
- Computed tomography
- Where
- Italy
- Volunteers
- 3,200 people
- Sponsor
- University of Padova
Myocardial Infarction, STEMI
Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
Rationale: the use of antiplatelet drugs (i.e. clopidogrel, ticagrelor or prasugrel) is crucial in the treatment of patients undergoing percutaneous coronary intervention (PCI) with stent implantation to prevent atherothrombotic…
- Trial name
- NCT01761786
- Testing
- CYP2C19 genotyping
- Where
- 10 sites in Belgium, Italy and 1 more
- Volunteers
- 2,700 people
- Sponsor
- Vera HM Deneer
Atrial Fibrillation, Atrial Appendage
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies following left atrial appendage closure (LAAC) in patients with non valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Atrial Appendage, Anticoagulants, Stroke
- Trial name
- APPENDAGE (NCT04796714)
- Testing
- Double antiplatelet therapy, Aspirin, Brain MRI
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Pre-diabetes
Resveratrol and First-degree Relatives of Type 2 Diabetic Patients
The main objective of the study is to investigate if resveratrol supplementation can improve overall and muscle-specific insulin sensitivity in first-degree relatives of type 2 diabetic patients.
- Trial name
- NCT02129595
- Testing
- resveratrol
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Maastricht University Medical Center
Non-ST Elevation Myocardial Infarction
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
- Trial name
- NCT03114995
- Testing
- Tirofiban
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Post Polypectomy Bleeding
Safety of Cold Snare Polypectomy in Patients With Uninterrupted Antiplatelet Agent
Polypectomy is regarded as high risk for bleeding. Several guidelines recommend continuous use of aspirin during polypectomy. However for clopidogrel, widely used antiplatelet agent, cessation of 5-7 is recommended.
- Trial name
- NCT04328987
- Testing
- cold snare polypectomy
- Where
- South Korea
- Volunteers
- 314 people
- Sponsor
- Incheon St.Mary's Hospital
Coronary Artery Disease, Percutaneous Coronary Intervention
Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)
The goal of this multicenter prospective clinical cohort study is to investigate the impact of early use of low-dose Ticagrelor-based dual antiplatelet agent therapy (TDAPT) (ticagrelor 120mg daily; l-TDAPT) as compared to…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- RICH (NCT05746416)
- Where
- South Korea
- Volunteers
- 977 people
- Sponsor
- Hanyang University Seoul Hospital
Ischemic Stroke, Antiplatelet Effect
Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke
This clinical trail will evaluate the effect of Sanchitongshu combined with antiplatelet drugs (Aspirin or Clopidogrel) in the treatment of high-risk ischemic stroke patients in adults.
- Trial name
- NCT04142151
- Testing
- Sanchitongshu, Aspirin, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Renal Failure, Coronary Artery Disease
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents
The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysulfone membranes and polyamide membranes)…
- Conditions
- Renal Failure, Coronary Artery Disease, Hemolysis
- Trial name
- NCT03330223
- Testing
- Clopidogrel group;Ticagrelor group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Peripheral Arterial Disease(PAD)
Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II
This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up…
- Trial name
- NCT06850207
- Volunteers
- 6,000 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine